Proanthocyanin Content in Cranberry CE Medicinal Products

被引:7
|
作者
Chrubasik-Hausmann, Sigrun [1 ]
Vlachojannis, Christian [1 ]
Zimmermann, Benno F. [2 ,3 ]
机构
[1] Univ Freiburg, Inst Forens Med, D-79104 Freiburg, Germany
[2] Univ Bonn, Dept Nutr & Food Sci, D-53115 Bonn, Germany
[3] Inst Prof Dr Georg Kurz GmbH, D-50933 Cologne, Germany
关键词
cranberry; proanthocyanins; recurrent urinary tract infections; CE medicinal products;
D O I
10.1002/ptr.5172
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The CE marking is a statutory marking for certain products sold within the European Economic Area. Medicinal products with a CE label are not regulated by the European Medicines Agency but are licensed according to the directives of the European Community. We have analysed the proanthocyanin (PAC) content of four cranberry CE products by both a photometric (DMAC method using 4-dimethylamino-cinnamic-aldehyde as colouring reagent) and a high-performance liquid chromatography assay and have compared the daily dosages recommended for the products by their manufacturers with benchmark doses obtained from the literature. For all CE products, the identified DMAC values for the PAC content per unit were below those declared. For two of the CE medicinal products, not even the manufacturers' maximum daily dosages have type A PAC contents that would have any chance of providing the health benefits promised on the product information sheets; the other two might have some chance, but only at maximum dosage (nine capsules per day for one of them). CE medicinal products should be better controlled by regulatory authorities to prevent consumers from buying and taking doses that are inadequate to provide the benefits claimed. Copyright (c) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:1612 / 1614
页数:3
相关论文
共 50 条
  • [41] Advanced therapy medicinal products
    Lozano-Blazquez, Ana
    Makridaki, Despina
    Plesan, Claudia Roxana
    Kohl, Stephanie
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (01) : 63 - 65
  • [42] Medicinal natural products in osteoporosis
    Sohretoglu, Didem
    Renda, Gulin
    MEDICINAL NATURAL PRODUCTS: A DISEASE-FOCUSED APPROACH, 2020, 55 : 327 - 372
  • [43] CFC AND REPLACEMENTS IN MEDICINAL PRODUCTS
    OLEJNICZAK, K
    BASS, R
    JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1991, 4 (03): : 205 - 209
  • [44] Medicinal Products and Environmental Pollution
    Noel Snell
    Pharmaceutical Medicine, 2024, 38 : 5 - 7
  • [45] Apitherapy Products for Medicinal Use
    Fratellone, Patrick M.
    Fratellone, Gregory
    JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2016, 22 (12) : 1020 - 1022
  • [46] Advanced therapy medicinal products
    Seitz, R.
    Schneider, C. K.
    Hengel, H.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2011, 54 (07) : 789 - 790
  • [47] Variations in veterinary medicinal products
    Kovacs, Dora
    MAGYAR ALLATORVOSOK LAPJA, 2021, 143 (09) : 544 - 544
  • [48] Orphan medicinal products in Europe
    Héron, E
    M S-MEDECINE SCIENCES, 2005, 21 : 66 - 68
  • [49] Precautionary principle and medicinal products
    Amédée-Manesme, O
    THERAPIE, 2000, 55 (06): : 675 - 679
  • [50] Pharmacovigliance of veterinary medicinal products
    Murphy, D
    Arthur, N
    IRISH VETERINARY JOURNAL, 2000, 53 (09) : 478 - 481